From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Combination of
TranylcypromineMonoamine oxidase inhibitor
TrifluoperazineTypical antipsychotic
Clinical data
Trade namesParstelin, Parmodalin, Jatrosom N, Stelapar
Routes of
Legal status
Legal status
  • In general: ℞ (Prescription only)

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3] It is still available in Italy with the name of Parmodalin.[5]

See also[edit]


  1. ^ Richard C. Dart (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
  2. ^ Stephen M. Stahl (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
  3. ^ a b c Straker M, Grauer H (1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Can Med Assoc J. 85 (3): 127–30. PMC 1848140. PMID 20326829.
  4. ^ Lothar Bruno Kalinowsky; Hanns Hippius; Helmfried E. Klein (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
  5. ^ "SIT - Parmodalin". Retrieved 2016-04-18.